Cellectis S.A (ALCLS) | Financial Analysis & Statements
Cellectis S.A. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
10.4M
Gross Profit
7.4M
71.15%
Operating Income
-17.4M
-166.90%
Net Income
-26.3M
-253.16%
EPS (Diluted)
€-0.26
Balance Sheet Metrics
Total Assets
324.7M
Total Liabilities
248.8M
Shareholders Equity
75.9M
Debt to Equity
3.28
Cash Flow Metrics
Operating Cash Flow
8.1M
Free Cash Flow
-10.8M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Cellectis S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 72.9M | 41.5M | 755.0K | 19.2M | 30.3M |
| Cost of Goods Sold | 9.8M | 9.2M | 737.0K | 1.8M | 1.8M |
| Gross Profit | 63.2M | 32.3M | 18.0K | 17.4M | 28.5M |
| Gross Margin % | 86.6% | 77.9% | 2.4% | 90.8% | 93.9% |
| Operating Expenses | |||||
| Research & Development | 93.5M | 90.5M | 87.6M | 97.5M | 117.8M |
| Selling, General & Administrative | 8.6M | 8.4M | 16.8M | 17.5M | 22.9M |
| Other Operating Expenses | -7.3M | -8.6M | -556.0K | -1.4M | -499.0K |
| Total Operating Expenses | 94.8M | 90.4M | 103.9M | 113.6M | 140.2M |
| Operating Income | -33.1M | -59.6M | -97.3M | -89.7M | -103.5M |
| Operating Margin % | -45.3% | -143.5% | -12,887.7% | -467.7% | -341.0% |
| Non-Operating Items | |||||
| Interest Income | 9.5M | 11.3M | 3.6M | 1.1M | 719.0K |
| Interest Expense | 8.1M | 7.5M | 5.3M | 3.8M | 4.2M |
| Other Non-Operating Income | -36.3M | 19.0M | -16.4M | 6.1M | 9.7M |
| Pre-tax Income | -68.0M | -36.8M | -116.5M | -98.6M | -96.8M |
| Income Tax | -423.0K | 0 | 371.0K | 87.0K | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -67.6M | -36.8M | -108.4M | -114.0M | -125.1M |
| Net Margin % | -92.7% | -88.6% | -14,363.3% | -594.8% | -412.3% |
| Key Metrics | |||||
| EBITDA | -3.5M | -28.4M | -76.3M | -82.4M | -88.2M |
| EPS (Basic) | - | €-0.41 | €-1.77 | €-2.33 | €-1.91 |
| EPS (Diluted) | - | €-0.41 | €-1.77 | €-2.33 | €-1.91 |
| Basic Shares Outstanding | - | 90566346 | 62283535 | 46773498 | 43584193 |
| Diluted Shares Outstanding | - | 90566346 | 62283535 | 46773498 | 43584193 |
Income Statement Trend
Cellectis S.A Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 61.5M | 143.3M | 136.7M | 89.8M | 185.6M |
| Short-term Investments | 147.1M | 117.1M | 67.1M | 7.9M | 499.0K |
| Accounts Receivable | 14.4M | 6.7M | 569.0K | 772.0K | 20.4M |
| Inventory | - | - | - | 0 | 0 |
| Other Current Assets | 330.0K | 298.0K | 345.0K | 538.0K | 50.0K |
| Total Current Assets | 236.2M | 287.1M | 233.0M | 143.8M | 225.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 94.8M | 92.9M | 91.5M | 90.6M | 95.2M |
| Goodwill | 535.0K | 1.1M | 672.0K | 718.0K | 1.9M |
| Intangible Assets | 535.0K | 1.1M | 672.0K | 718.0K | 1.9M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 20.4M | 12.0M | -1.0K | - | 3.0K |
| Total Non-Current Assets | 88.5M | 96.5M | 101.3M | 117.4M | 156.6M |
| Total Assets | 324.7M | 383.5M | 334.3M | 261.2M | 382.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 17.3M | 18.7M | 19.1M | 21.5M | 23.8M |
| Short-term Debt | 11.8M | 13.2M | 13.7M | 12.8M | 10.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 7.9M | 12.5M | 978.0K | 15.7M | 1.3M |
| Total Current Liabilities | 145.8M | 166.3M | 155.1M | 63.0M | 49.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 78.9M | 78.2M | 71.4M | 62.9M | 90.3M |
| Deferred Tax Liabilities | - | 0 | 158.0K | - | - |
| Other Non-Current Liabilities | 738.0K | 882.0K | 12.9M | 7.0M | 1.9M |
| Total Non-Current Liabilities | 103.1M | 86.2M | 94.4M | 72.3M | 96.3M |
| Total Liabilities | 248.8M | 252.5M | 249.6M | 135.3M | 145.6M |
| Equity | |||||
| Common Stock | 5.9M | 5.9M | 4.4M | 3.0M | 2.9M |
| Retained Earnings | -334.1M | -329.6M | -405.8M | -439.5M | -698.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 75.9M | 131.0M | 84.7M | 125.9M | 236.5M |
| Key Metrics | |||||
| Total Debt | 90.7M | 91.5M | 85.1M | 75.8M | 100.9M |
| Working Capital | 90.5M | 120.8M | 77.9M | 80.8M | 176.1M |
Balance Sheet Composition
Cellectis S.A Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -67.6M | -36.8M | -116.8M | -98.7M | -96.7M |
| Depreciation & Amortization | 20.1M | 19.8M | 18.5M | 18.4M | 14.2M |
| Stock-Based Compensation | 6.1M | 3.2M | 5.2M | 6.0M | 11.5M |
| Working Capital Changes | -41.6M | 53.7M | 48.9M | -5.7M | -12.3M |
| Operating Cash Flow | -48.5M | 18.6M | -26.1M | -71.2M | -89.9M |
| Investing Activities | |||||
| Capital Expenditures | -2.4M | -2.6M | -1.1M | -2.4M | -18.5M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -159.8M | -162.8M | - | - | -143.0K |
| Investment Sales | 133.8M | 63.8M | - | 126.0K | 15.0M |
| Investing Cash Flow | -28.3M | -101.5M | -2.7M | -2.3M | -3.7M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | -569.0K | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Debt Issuance | 0 | 23.2M | 29.7M | 5.8M | 0 |
| Debt Repayment | -16.2M | -16.1M | -16.2M | -12.4M | -10.6M |
| Financing Cash Flow | -16.1M | 90.0M | 81.4M | -7.2M | 34.0M |
| Free Cash Flow | -42.9M | 19.1M | -25.8M | -89.9M | -123.1M |
| Net Change in Cash | -93.0M | 7.0M | 52.6M | -80.7M | -59.6M |
Cash Flow Trend
Cellectis S.A Key Financial Ratios
Valuation Ratios
Forward P/E
-2.09
Price to Book
3.69
Price to Sales
4.18
PEG Ratio
-2.09
Profitability Ratios
Profit Margin
-84.92%
Operating Margin
-142.14%
Return on Equity
-65.33%
Return on Assets
-5.84%
Financial Health
Current Ratio
1.62
Debt to Equity
114.22
Beta
2.71
Per Share Data
EPS (TTM)
€-0.58
Book Value per Share
€0.90
Revenue per Share
€0.79
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALCLS | 336.0M | - | 3.69 | -65.33% | -84.92% | 114.22 |
| Abivax SA | 7.6B | -19.88 | 16.56 | -135.58% | 0.00% | 7.05 |
| Nanobiotix | 1.4B | - | - | 28.36% | -73.52% | -1.13 |
| Medincell S.A | 831.6M | -37.35 | - | 112.65% | -61.49% | -2.40 |
| BNP Paribas Easy | 527.3M | 22.65 | - | -96.39% | -27.22% | 2.22 |
Financial data is updated regularly. All figures are in the company's reporting currency.